BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rizzetto M. Efficacy of lamivudine in HBeAg-negative chronic hepatitis B. J Med Virol. 2002;66:435-451. [PMID: 11857520 DOI: 10.1002/jmv.2164] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Liu CJ, Huang WL, Chen PJ, Lai MY, Kao JH, Chen DS. End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B. World J Gastroenterol 2004; 10(24): 3574-3578 [PMID: 15534909 DOI: 10.3748/wjg.v10.i24.3574] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
2 Davis J. Preventing hepatitis B virus reactivation following immunosuppressive therapy. Internal Medicine Journal 2008;38:617-617. [DOI: 10.1111/j.1445-5994.2008.01652.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Zampino R, Marrone A, Adinolfi LE, Ruggiero G. Treatment of chronic hepatitis B: efficacy of current drugs and prospects for the future. Expert Rev Clin Immunol 2006;2:915-29. [PMID: 20476979 DOI: 10.1586/1744666X.2.6.915] [Reference Citation Analysis]
4 Lai CJ, Terrault NA. Antiviral therapy in patients with chronic hepatitis B and cirrhosis. Gastroenterol Clin North Am 2004;33:629-54, x-xi. [PMID: 15324948 DOI: 10.1016/j.gtc.2004.05.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
5 Rizzetto M, Marzano A, Lagget M. Treatment of hepatitis B e antigen-negative chronic hepatitis B with lamivudine. J Hepatol. 2003;39 Suppl 1:S168-S171. [PMID: 14708698 DOI: 10.1016/s0168-8278(03)00311-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
6 Gaia S, Marzano A, Smedile A, Barbon V, Abate ML, Olivero A, Lagget M, Paganin S, Fadda M, Niro G. Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B. Aliment Pharmacol Ther. 2004;20:281-287. [PMID: 15274664 DOI: 10.1111/j.1365-2036.2004.02073.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
7 Leemans WF, Ter Borg MJ, de Man RA. Review article: Success and failure of nucleoside and nucleotide analogues in chronic hepatitis B. Aliment Pharmacol Ther 2007;26 Suppl 2:171-82. [PMID: 18081660 DOI: 10.1111/j.1365-2036.2007.03481.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
8 Elefsiniotis IS, Moulakakis A, Pantazis KD, Glynou I, Ketikoglou I, Vezali E, Kada H, Tsianos E. Relationship between serum b2-microglobulin levels and virological breakthrough in HBeAg-negative chronic hepatitis B patients, under long-term treatment schedules including lamivudine. World J Gastroenterol 2005; 11(13): 1922-1928 [PMID: 15800981 DOI: 10.3748/wjg.v11.i13.1922] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
9 Elefsiniotis IS, Ketikoglou I, Kafiri G, Pantazis KD, Moulakakis A, Mavrogiannis C. Plasma pituitary adenylate cyclase activating polypeptide (PACAP) levels in chronic hepatitis B patients under lamivudine treatment: . European Journal of Gastroenterology & Hepatology 2003;15:1209-16. [DOI: 10.1097/00042737-200311000-00010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
10 Soon DK, Lowe SL, Teng CH, Yeo KP, McGill J, Wise SD. Safety and efficacy of alamifovir in patients with chronic hepatitis B virus infection. J Hepatol 2004;41:852-8. [PMID: 15519660 DOI: 10.1016/j.jhep.2004.07.028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
11 Lee SH, Kim HS, Byun IS, Jeong SW, Kim SG, Jang JY, Kim YS, Kim BS. Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy. J Med Virol. 2012;84:217-222. [PMID: 22170540 DOI: 10.1002/jmv.23191] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
12 Zoulim F. Antiviral therapy of chronic hepatitis B. Antiviral Res. 2006;71:206-215. [PMID: 16716414 DOI: 10.1016/j.antiviral.2006.04.003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 3.3] [Reference Citation Analysis]
13 Conjeevaram HS, Lok AS. Management of chronic hepatitis B. Journal of Hepatology 2003;38:90-103. [DOI: 10.1016/s0168-8278(02)00431-2] [Cited by in Crossref: 122] [Cited by in F6Publishing: 28] [Article Influence: 6.4] [Reference Citation Analysis]
14 Yurdaydin C, Bozkaya H, Cetinkaya H, Sahin T, Karaoğuz D, Törüner M, Erkan O, Heper AO, Erden E, Bozdayi AM, Uzunalimoğlu O. Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B. J Viral Hepat 2005;12:262-8. [PMID: 15850466 DOI: 10.1111/j.1365-2893.2005.00566.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
15 Li XM, Yang YB, Hou HY, Shi ZJ, Shen HM, Teng BQ, Li AM, Shi MF, Zou L. Interruption of HBV intrauterine transmission: A clinical study. World J Gastroenterol 2003; 9(7): 1501-1503 [PMID: 12854150 DOI: 10.3748/wjg.v9.i7.1501] [Cited by in CrossRef: 85] [Cited by in F6Publishing: 83] [Article Influence: 4.5] [Reference Citation Analysis]
16 León P, Pozo F, Echevarría JM. Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain. Enferm Infecc Microbiol Clin 2004;22:133-7. [PMID: 14987532 DOI: 10.1016/s0213-005x(04)73051-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
17 Asmuth DM, Nguyen HH, Melcher GP, Cohen SH, Pollard RB. Treatments for hepatitis B. Clin Infect Dis. 2004;39:1353-1362. [PMID: 15494913 DOI: 10.1086/425010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
18 Lagget M, Rizzetto M. Current pharmacotherapy for the treatment of chronic hepatitis B. Expert Opin Pharmacother. 2003;4:1821-1827. [PMID: 14521491 DOI: 10.1517/14656566.4.10.1821] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
19 Veenstra DL, Sullivan SD, Lai MY, Lee CM, Tsai CM, Patel KK. HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan. Value Health 2008;11:131-8. [PMID: 18380625 DOI: 10.1111/j.1524-4733.2007.00221.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
20 Kobayashi M, Suzuki F, Akuta N, Suzuki Y, Arase Y, Ikeda K, Hosaka T, Sezaki H, Kobayashi M, Iwasaki S. Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C. J Med Virol. 2006;78:1276-1283. [PMID: 16927289 DOI: 10.1002/jmv.20701] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
21 Yoo BC, Kim JH, Kim TH, Koh KC, Um SH, Kim YS, Lee KS, Han BH, Chon CY, Han JY, Ryu SH, Kim HC, Byun KS, Hwang SG, Kim BI, Cho M, Yoo K, Lee HJ, Hwang JS, Kim YS, Lee YS, Choi SK, Lee YJ, Yang JM, Park JW, Lee MS, Kim DG, Chung YH, Cho SH, Choi JY, Kweon YO, Lee HY, Jeong SH, Yoo HW, Lee HS. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007;46:1041-8. [PMID: 17647293 DOI: 10.1002/hep.21800] [Cited by in Crossref: 82] [Cited by in F6Publishing: 68] [Article Influence: 5.5] [Reference Citation Analysis]